LABELS · dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
IMKELDI
Open original source → · Download preserved record
Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.
- Label effective date
- 2024-12-05
- Captured
- 2026-09-09T23:38:02.384588+00:00
- Current indication reconciliation
- Not reconciled
Indications and usage: exact source text
- 1 INDICATIONS AND USAGE Imkeldi is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). 1.4 Pediatric Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.
Full extracted label fields
- application numbers
- NDA219097
- boxed warning exact
- brand names
- IMKELDI
- current indication status
- not_reconciled
- dailymed set url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26658bb7-9ba1-a10e-e063-6394a90a172e
- generic names
- IMATINIB ORAL
- id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- indications and usage exact
- 1 INDICATIONS AND USAGE Imkeldi is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). 1.4 Pediatric Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.
- indications and usage tables exact
- is original packager
- true
- manufacturer names
- Shorla Oncology Inc.,
- matched search terms
- leukemia
- tumors
- malignant
- myelodysplastic
- mastocytosis
- myeloproliferative
- package ndcs
- 81927-201-01
- product ndcs
- 81927-201
- product types
- HUMAN PRESCRIPTION DRUG
- recent major changes exact
- record type
- complete_spl_indications_section_candidate
- routes
- ORAL
- rxcuis
- 2699831
- 2699837
- source batch
- file
- /private/tmp/cancer-full-research/indications/raw/labels-00700.json
- meta
- disclaimer
- Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
- last updated
- 2026-09-09
- results
- limit
- 100
- skip
- 700
- total
- 830
- sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl effective time
- 20241205
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- substance names
- IMATINIB MESYLATE
- uniis
- 8A1O1M485B
- verification flags
- oncology_keyword_candidate_not_clinically_classified
- spl_text_not_verified_identical_to_latest_approved_label
- individual_indications_not_split_or_reconciled
Drugs@FDA application source records
- application number
- NDA219097
- payload
- all indexed label documents
- Appl No
- 219097
- Application Docs Date
- 2024-11-25 00:00:00
- Application Docs ID
- 80358
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219097s000lbl.pdf
- Submission No
- 1
- Submission Type
- ORIG
- all submission records
- Appl No
- 219097
- Review Priority
- STANDARD
- Submission Class Code ID
- 12
- Submission No
- 1
- Submission Status
- AP
- Submission Status Date
- 2024-11-22 00:00:00
- Submission Type
- ORIG
- Submissions Public Notes
- application number
- NDA219097
- approval interpretation
- Application linkage and approved submission are not indication-level current approval verification
- current indication status
- not_reconciled
- drugsfda url
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219097
- has approved submission record
- true
- latest approved submission date
- 2024-11-22
- latest label selection rule
- max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
- latest posted label documents
- Appl No
- 219097
- Application Docs Date
- 2024-11-25 00:00:00
- Application Docs ID
- 80358
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219097s000lbl.pdf
- Submission No
- 1
- Submission Type
- ORIG
- official application record
- Appl No
- 219097
- Appl Public Notes
- Appl Type
- NDA
- Sponsor Name
- SHORLA ONCOLOGY
- openfda application present
- true
- products
- Active Ingredient
- IMATINIB MESYLATE
- Appl No
- 219097
- Drug Name
- IMKELDI
- Form
- SOLUTION;ORAL
- Product No
- 001
- Reference Drug
- 1
- Reference Standard
- 1
- Strength
- EQ 80MG BASE/ML
- marketing status
- Prescription
Source passages and status connections
Passage 1 · positive indication candidate
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 421
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE Imkeldi is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha ther
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-8a9b1a3e521aa68a27bd
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-e9f6bd4a48f531aa69b2
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- end
- 63
- end exclusive
- true
- exact text
- is a kinase inhibitor indicated
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 32
- qualifier mentions
- context exact
- e inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positiv
- kind
- age
- polarity
- not_inferred
- span
- end
- 107
- end exclusive
- true
- exact text
- adult
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 102
- context exact
- r indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leuke
- kind
- age
- polarity
- not_inferred
- span
- end
- 130
- end exclusive
- true
- exact text
- pediatric patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 112
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 221
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE Imkeldi is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 0
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 2 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 429
- end exclusive
- true
- exact text
- E Imkeldi is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 22
- current approval status
- not_reconciled
- duplicate text group
- dup-580fbe20ad7bbcf27885
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-5824cd54320326896918
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 229
- end exclusive
- true
- exact text
- ( 1.1 )
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 222
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 3 · positive indication candidate
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 625
- end exclusive
- true
- exact text
- i is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome pos
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 30
- current approval status
- not_reconciled
- duplicate text group
- dup-73edf8490446a182e4e4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-e7226d548d43aa2ea697
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- end
- 63
- end exclusive
- true
- exact text
- is a kinase inhibitor indicated
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 32
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 425
- end exclusive
- true
- exact text
- Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 230
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 4 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 633
- end exclusive
- true
- exact text
- 1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive ac
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 226
- current approval status
- not_reconciled
- duplicate text group
- dup-0d465387b7d387d8512a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-208b29445d8c819d3054
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 433
- end exclusive
- true
- exact text
- ( 1.2 )
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 426
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 5 · positive indication candidate
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 749
- end exclusive
- true
- exact text
- ents with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/m
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 234
- current approval status
- not_reconciled
- duplicate text group
- dup-e14f14a729baa8113162
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-7923088eb2489ae87cbc
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- end
- 63
- end exclusive
- true
- exact text
- is a kinase inhibitor indicated
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 32
- qualifier mentions
- context exact
- Adult patients with relapsed or refractory Philadelphia chromosome positiv
- kind
- age
- polarity
- not_inferred
- span
- end
- 448
- end exclusive
- true
- exact text
- Adult patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 434
- context exact
- Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 497
- end exclusive
- true
- exact text
- relapsed or refractory Philadelphia chromos
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 454
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 549
- end exclusive
- true
- exact text
- Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 434
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 6 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 757
- end exclusive
- true
- exact text
- e (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloprol
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 350
- current approval status
- not_reconciled
- duplicate text group
- dup-086c0639097c9855edb9
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-e2eafef2ffd4f8fa5a12
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 557
- end exclusive
- true
- exact text
- ( 1.3 )
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 550
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 7 · positive indication candidate
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 903
- end exclusive
- true
- exact text
- or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with agg
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 358
- current approval status
- not_reconciled
- duplicate text group
- dup-4a52b211c6eaf6df59b2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-4d2c4ebc5c167b0f1dff
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- end
- 63
- end exclusive
- true
- exact text
- is a kinase inhibitor indicated
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 32
- qualifier mentions
- context exact
- Pediatric patients with newly diagnosed Philadelphia chromosome positive acute
- kind
- age
- polarity
- not_inferred
- span
- end
- 576
- end exclusive
- true
- exact text
- Pediatric patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 558
- context exact
- chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 702
- end exclusive
- true
- exact text
- in combination with chemotherapy
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 670
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 703
- end exclusive
- true
- exact text
- Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 558
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 8 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 911
- end exclusive
- true
- exact text
- itive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 504
- current approval status
- not_reconciled
- duplicate text group
- dup-9ff78302824f1ca634b6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-7489676b96676acc6711
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 711
- end exclusive
- true
- exact text
- ( 1.4 )
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 704
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 9 · positive indication candidate
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1071
- end exclusive
- true
- exact text
- ute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HE
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 512
- current approval status
- not_reconciled
- duplicate text group
- dup-8c9a5c8e0bb52b5506e8
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-a17c63bf2d6b9398f7d5
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- end
- 63
- end exclusive
- true
- exact text
- is a kinase inhibitor indicated
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 32
- qualifier mentions
- context exact
- Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD)
- kind
- age
- polarity
- not_inferred
- span
- end
- 726
- end exclusive
- true
- exact text
- Adult patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 712
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 871
- end exclusive
- true
- exact text
- Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 712
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 10 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1079
- end exclusive
- true
- exact text
- combination with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/o
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 672
- current approval status
- not_reconciled
- duplicate text group
- dup-49194f8cb404403cf30a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-d1e50659c9716a3e8a8a
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 879
- end exclusive
- true
- exact text
- ( 1.5 )
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 872
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 11 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1212
- end exclusive
- true
- exact text
- tion with chemotherapy. ( 1.4 ) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridiza
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 680
- current approval status
- not_reconciled
- duplicate text group
- dup-b89764a9c9e5eb31abeb
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-a14296757a80d99fa996
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Adult patients with aggressive systemic mastocytosis (ASM) without the D81
- kind
- age
- polarity
- not_inferred
- span
- end
- 894
- end exclusive
- true
- exact text
- Adult patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 880
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 1012
- end exclusive
- true
- exact text
- Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 880
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 12 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1220
- end exclusive
- true
- exact text
- rived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FI
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 813
- current approval status
- not_reconciled
- duplicate text group
- dup-9798ca47b76b5bf9f1c2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-ef150d13b6a42ad4d69f
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 1020
- end exclusive
- true
- exact text
- ( 1.6 )
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1013
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 13 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1557
- end exclusive
- true
- exact text
- owth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastr
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 821
- current approval status
- not_reconciled
- duplicate text group
- dup-0d821a9ac8183cddd896
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-c562838c752cd178cc33
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosino
- kind
- age
- polarity
- not_inferred
- span
- end
- 1035
- end exclusive
- true
- exact text
- Adult patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1021
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 1357
- end exclusive
- true
- exact text
- Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1021
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 14 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1565
- end exclusive
- true
- exact text
- (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointesti
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1158
- current approval status
- not_reconciled
- duplicate text group
- dup-a049b0c904b8778e0cce
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-a1378d31b691a5d1ff79
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 1365
- end exclusive
- true
- exact text
- ( 1.7 )
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1358
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 15 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1667
- end exclusive
- true
- exact text
- nal analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1166
- current approval status
- not_reconciled
- duplicate text group
- dup-880cbfb4ae1ec8d869a2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-0c8f782baeaf335c5eba
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Adult patients with unresectable, recurrent and/or metastatic dermatofibro
- kind
- age
- polarity
- not_inferred
- span
- end
- 1380
- end exclusive
- true
- exact text
- Adult patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1366
- context exact
- Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1460
- end exclusive
- true
- exact text
- metastatic dermatofibrosarcoma protuberans
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1417
- context exact
- Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberan
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1398
- end exclusive
- true
- exact text
- unresectable
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1386
- context exact
- Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1444
- end exclusive
- true
- exact text
- recurrent and/or metastatic dermatofibrosarc
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1400
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 1467
- end exclusive
- true
- exact text
- Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP).
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1366
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 16 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1675
- end exclusive
- true
- exact text
- for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) pos
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1268
- current approval status
- not_reconciled
- duplicate text group
- dup-95369ed29dfea7d92170
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-4294e7b1acc736f8e514
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 1475
- end exclusive
- true
- exact text
- ( 1.8 )
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1468
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 17 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1791
- end exclusive
- true
- exact text
- ents with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed ad
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1276
- current approval status
- not_reconciled
- duplicate text group
- dup-4bfc67997ed18499ff06
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-8ec3ffd6bb1f6b7b8bf6
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1574
- end exclusive
- true
- exact text
- metastatic malignant gastrointestinal strom
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1531
- context exact
- Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1558
- end exclusive
- true
- exact text
- unresectable and/or metastatic malignant gastro
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1511
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 1591
- end exclusive
- true
- exact text
- Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1476
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 18 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1886
- end exclusive
- true
- exact text
- ctable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1392
- current approval status
- not_reconciled
- duplicate text group
- dup-4d9de3b7861973017622
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-eae035c5b11cca2eda0f
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST.
- kind
- age
- polarity
- not_inferred
- span
- end
- 1636
- end exclusive
- true
- exact text
- adult patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1622
- context exact
- ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1643
- end exclusive
- true
- exact text
- Adjuvant treatment of adult patients follow
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1600
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 1686
- end exclusive
- true
- exact text
- ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1592
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 19 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1895
- end exclusive
- true
- exact text
- th Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in c
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1487
- current approval status
- not_reconciled
- duplicate text group
- dup-40383da14240ff19604d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-ae46e5900823fe77ead3
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 1695
- end exclusive
- true
- exact text
- ( 1.10 )
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1687
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 20 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2108
- end exclusive
- true
- exact text
- D117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). ( 1.9 ) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. ( 1.10 ) 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast cr
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1496
- current approval status
- not_reconciled
- duplicate text group
- dup-323347745892bf7118d9
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-8a7b023dff8b88bc9771
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positiv
- kind
- age
- polarity
- not_inferred
- span
- end
- 1794
- end exclusive
- true
- exact text
- adult
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1789
- context exact
- hronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leuke
- kind
- age
- polarity
- not_inferred
- span
- end
- 1817
- end exclusive
- true
- exact text
- pediatric patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1799
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 1908
- end exclusive
- true
- exact text
- 1.1 Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1696
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 21 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2395
- end exclusive
- true
- exact text
- gnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). 1.4 Pediatric Patien
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1709
- current approval status
- not_reconciled
- duplicate text group
- dup-78a6e54c049032bf94a2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-840bd42c335ce5d50415
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 2195
- end exclusive
- true
- exact text
- 1.2 Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1909
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 22 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2574
- end exclusive
- true
- exact text
- terferon-alpha (IFN) Therapy Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. 1.3 Adult Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). 1.4 Pediatric Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 1996
- current approval status
- not_reconciled
- duplicate text group
- dup-6bf366bef9723b7bc635
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-b5b752c79485690e6be8
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- 1.3 Adult Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients
- kind
- age
- polarity
- not_inferred
- span
- end
- 2214
- end exclusive
- true
- exact text
- Adult Patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2200
- context exact
- Adult Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positiv
- kind
- age
- polarity
- not_inferred
- span
- end
- 2273
- end exclusive
- true
- exact text
- Adult patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2259
- context exact
- Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2322
- end exclusive
- true
- exact text
- relapsed or refractory Philadelphia chromos
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2279
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 2374
- end exclusive
- true
- exact text
- 1.3 Adult Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2196
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 23 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2787
- end exclusive
- true
- exact text
- feron-alpha therapy. 1.3 Adult Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). 1.4 Pediatric Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (PDGFR) gene re-arran
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2175
- current approval status
- not_reconciled
- duplicate text group
- dup-4c7f43feb76d58cfba32
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-632d1b02534e2fa6dfae
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- 1.4 Pediatric Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patie
- kind
- age
- polarity
- not_inferred
- span
- end
- 2397
- end exclusive
- true
- exact text
- Pediatric Patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2379
- context exact
- iatric Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute
- kind
- age
- polarity
- not_inferred
- span
- end
- 2460
- end exclusive
- true
- exact text
- Pediatric patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2442
- context exact
- chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2586
- end exclusive
- true
- exact text
- in combination with chemotherapy
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2554
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 2587
- end exclusive
- true
- exact text
- 1.4 Pediatric Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2375
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 24 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2995
- end exclusive
- true
- exact text
- Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrom
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2388
- current approval status
- not_reconciled
- duplicate text group
- dup-2ba3c62663535204ba5e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-311c987f1ef729a58b79
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated
- kind
- age
- polarity
- not_inferred
- span
- end
- 2660
- end exclusive
- true
- exact text
- Adult patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2646
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 2795
- end exclusive
- true
- exact text
- 1.5 Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2588
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 25 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3165
- end exclusive
- true
- exact text
- odysplastic/Myeloproliferative Diseases (MDS/MPD) Adult patients with myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion k
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2596
- current approval status
- not_reconciled
- duplicate text group
- dup-a2f3de14a616a29b485b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-cae096a34c8a0dabb91c
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-K
- kind
- age
- polarity
- not_inferred
- span
- end
- 2853
- end exclusive
- true
- exact text
- Adult patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2839
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 2965
- end exclusive
- true
- exact text
- 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2796
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 26 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3570
- end exclusive
- true
- exact text
- (PDGFR) gene re-arrangements. 1.6 Aggressive Systemic Mastocytosis (ASM) Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown. 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2766
- current approval status
- not_reconciled
- duplicate text group
- dup-1b4ce8f8cf01e82d2959
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-1bc9bdbdc34428ef222b
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- c Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic
- kind
- age
- polarity
- not_inferred
- span
- end
- 3060
- end exclusive
- true
- exact text
- Adult patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3046
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 3370
- end exclusive
- true
- exact text
- 1.7 Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 2966
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 27 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3708
- end exclusive
- true
- exact text
- (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant t
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3171
- current approval status
- not_reconciled
- duplicate text group
- dup-350178f1667fa5715b48
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-0909862b4f7b4b6dc0f5
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibro
- kind
- age
- polarity
- not_inferred
- span
- end
- 3428
- end exclusive
- true
- exact text
- Adult patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3414
- context exact
- s (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3507
- end exclusive
- true
- exact text
- metastatic dermatofibrosarcoma protuberans
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3465
- context exact
- Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberan
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3446
- end exclusive
- true
- exact text
- unresectable
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3434
- context exact
- arcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3492
- end exclusive
- true
- exact text
- recurrent and/or metastatic dermatofibrosarc
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3448
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 3508
- end exclusive
- true
- exact text
- 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3371
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 28 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3799
- end exclusive
- true
- exact text
- CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown. 1.8 Dermatofibrosarcoma Protuberans (DFSP) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3309
- current approval status
- not_reconciled
- duplicate text group
- dup-941ee5928ecc1012880f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-131ea8ca40355990ee05
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- IST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3655
- end exclusive
- true
- exact text
- metastatic malignant gastrointestinal strom
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3612
- context exact
- al Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3639
- end exclusive
- true
- exact text
- unresectable and/or metastatic malignant gastro
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3592
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 3665
- end exclusive
- true
- exact text
- 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3509
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 29 · unclassified context
- application numbers
- NDA219097
- brand names
- IMKELDI
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3799
- end exclusive
- true
- exact text
- etastatic dermatofibrosarcoma protuberans. 1.9 Kit+ Gastrointestinal Stromal Tumors (GIST) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3466
- current approval status
- not_reconciled
- duplicate text group
- dup-85440fea4756d8e3a46c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- IMATINIB ORAL
- id
- ind-span-0d7277f32c6e70a5e124
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive
- kind
- age
- polarity
- not_inferred
- span
- end
- 3734
- end exclusive
- true
- exact text
- adult patients
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3720
- context exact
- 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of K
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3714
- end exclusive
- true
- exact text
- Adjuvant Treatment of GIST Adjuvant treatme
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3671
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source defined aliases
- source span
- end
- 3799
- end exclusive
- true
- exact text
- 1.10 Adjuvant Treatment of GIST Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.
- label id
- dead98c8-2ac0-4fe6-890a-cc8c92ddcffc
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- c4f5a7ef3d5a484044301dc942df9548ed06366ff82fec4f1051d5f3d5e14492
- start
- 3666
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%22dead98c8-2ac0-4fe6-890a-cc8c92ddcffc%22
- spl effective date
- 2024-12-05
- spl set id
- 26658bb7-9ba1-a10e-e063-6394a90a172e
- spl version
- 2
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Preserved source evidence · Not medical advice
Triangle